The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer
Ortega, S. (Universidad de Zaragoza) ; Mínguez, J.A. ; Aramendía, J.M. ; Santisteban, M. ; MartinezRegueira, F. ; Martí-Cruchaga, P. ; Alcázar, J.L. ; Jurado, M.
Resumen: Objective: Analyze the effect on survival of secondary cytoreduction surgery (SCS) in treatment of first recurrence platinumsensitive epithelial ovarian cancer (REOC).
Methods: Retrospective analysis of patients with first REOC who had platinum timefree interval (TFIp) > 6 months and were treated either with SCS followed by chemotherapy or chemotherapy only (CT). Clinical data such as patient’s performance status and number of sites with metastases were specifically assessed. The primary endpoint was overall survival (OS).
Results: Seventyone patients were treated either by SCS (n = 37) or CT (n = 34). Complete resection after SCS was achieved in 89% of patients. After a median followup of 51.2 months, median OS, and progressionfree survival (PFS) were 68.2 and 21.6 months, respectively, for the whole series of the SCS patients had better survival and disease progression survival than the CT only patients (HR: 0.33, 95%CI: 0.170.6; p= 0.001) and (HR: 0.28, 95%CI: 0.150.5; p= 0.001), respectively. TFIp < 12 months and multiple metastases were most important prognostic factors for risk of death (HR: 7.7 and 6.2, respectively) and recurrence (HR: 5.8 and 3.8, respectively). Probability to undergo successful SCS is related to oligometastatic disease and no residual disease after first surgery (OR: 30.0 and 5.9, respectively).
Conclusions: In women with REOC oligometastatic disease and no residual disease at first surgery are associated with successful SCS. In these patients oligometastatic disease and long platinum TFI are associated with improved probability of survival.
Idioma: Inglés
DOI: 10.31083/J.EJGO.2020.04.8051
Año: 2020
Publicado en: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY 41, 4 (2020), 523-530
ISSN: 0392-2936
Factor impacto JCR: 0.196 (2020)
Categ. JCR: ONCOLOGY rank: 240 / 242 = 0.992 (2020) - Q4 - T3
Categ. JCR: OBSTETRICS & GYNECOLOGY rank: 81 / 83 = 0.976 (2020) - Q4 - T3
Factor impacto SCIMAGO: 0.15 - Oncology (Q4) - Obstetrics and Gynecology (Q4)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Cirugía (Dpto. Cirugía)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
Exportado de SIDERAL (2021-09-02-10:53:41)
Visitas y descargas
Methods: Retrospective analysis of patients with first REOC who had platinum timefree interval (TFIp) > 6 months and were treated either with SCS followed by chemotherapy or chemotherapy only (CT). Clinical data such as patient’s performance status and number of sites with metastases were specifically assessed. The primary endpoint was overall survival (OS).
Results: Seventyone patients were treated either by SCS (n = 37) or CT (n = 34). Complete resection after SCS was achieved in 89% of patients. After a median followup of 51.2 months, median OS, and progressionfree survival (PFS) were 68.2 and 21.6 months, respectively, for the whole series of the SCS patients had better survival and disease progression survival than the CT only patients (HR: 0.33, 95%CI: 0.170.6; p= 0.001) and (HR: 0.28, 95%CI: 0.150.5; p= 0.001), respectively. TFIp < 12 months and multiple metastases were most important prognostic factors for risk of death (HR: 7.7 and 6.2, respectively) and recurrence (HR: 5.8 and 3.8, respectively). Probability to undergo successful SCS is related to oligometastatic disease and no residual disease after first surgery (OR: 30.0 and 5.9, respectively).
Conclusions: In women with REOC oligometastatic disease and no residual disease at first surgery are associated with successful SCS. In these patients oligometastatic disease and long platinum TFI are associated with improved probability of survival.
Idioma: Inglés
DOI: 10.31083/J.EJGO.2020.04.8051
Año: 2020
Publicado en: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY 41, 4 (2020), 523-530
ISSN: 0392-2936
Factor impacto JCR: 0.196 (2020)
Categ. JCR: ONCOLOGY rank: 240 / 242 = 0.992 (2020) - Q4 - T3
Categ. JCR: OBSTETRICS & GYNECOLOGY rank: 81 / 83 = 0.976 (2020) - Q4 - T3
Factor impacto SCIMAGO: 0.15 - Oncology (Q4) - Obstetrics and Gynecology (Q4)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Cirugía (Dpto. Cirugía)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. Exportado de SIDERAL (2021-09-02-10:53:41)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2020-10-20, última modificación el 2021-09-02